A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury.

Shiraz Moosa, Muhammed; Maartens, Gary; Gunter, Hannah; Allie, Shaazia; F Chughlay, Mohamed; Setshedi, Mashiko; Wasserman, Sean; F Stead, David; Hickman, Nicole; Stewart, Annemie; Sonderup, Mark; Wendy Spearman, Catherine; Cohen, Karen

doi:10.1093/cid/ciaa1255

Public

A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury.

Shared by NobleBlocks on Nov 2, 2021 • 12:00 AM UTC

Authors:

Muhammed Shiraz Moosa

Gary Maartens

Hannah Gunter

Abstract

BACKGROUND: Liver injury is a common complication of anti-tuberculosis therapy. N-acetylcysteine (NAC) used in patients with paracetamol toxicity with limited evidence of benefit in liver injury due to other causes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess...

Subject

N-acetylcysteine

anti-tuberculosis therapy

drug-induced liver injury

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!